J Neurogastroenterol Motil.
2016 Jul;22(3):355-366. 10.5056/jnm15150.
Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region
- Affiliations
-
- 1Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia. klgoh56@gmail.com
- 2Department of Internal Medicine, Catholic University of Korea, Seoul, Korea.
- 3Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan ROC.
- 4Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
- 5Division of Gastroenterology, Chulalongkorn University, Bangkok, Thailand.
- 6Division of Gastroenterology, Department of Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- 7Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea.
- 8Department of Internal Medicine, University of Indonesia, Depok, Indonesia.
- 9Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- 10Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
- 11Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital & Chang Gung University, Taoyuan, Taiwan ROC.
- 12Medical Affairs, Takeda Pharmaceuticals (Asia Pacific) Pte Ltd, Singapore.
- 13St. Luke's College of Medicine-William H. Quasha Memorial, Quezon City, Philippines.
- 14Faculty of Medicine and Surgery, University of Santo Tomas Hospital, Manila, Philippines.
- 15Department of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan ROC.
- KMID: 2327943
- DOI: http://doi.org/10.5056/jnm15150
Abstract
- Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as increased healthcare use. Proton pump inhibitors (PPIs) are currently the most effective treatment for gastroesophageal reflux disease. However, there are limitations associated with these drugs in terms of partial and non-response. Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration. Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. Dexlansoprazole has also been shown to achieve good plasma concentration regardless of administration with food, providing flexible dosing. Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed. This review discusses the role of the new generation PPI, dexlansoprazole, in the treatment of gastroesophageal reflux disease in Asia.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Proton Pump Inhibitor for Gastroesophageal Reflux Disease: Intelligent Prescription
- Nonerosive Reflux Disease (NERD) - An Update
- Unmet Needs in the Treatment of Gastroesophageal Reflux Disease
- Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker
- Can Esophageal Baseline Impedance Predict Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease?
